title: MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients.
abstract: Recently, a gain-of-function MPL mutation, MPLW515L, was described in patients with JAK2V617F-negative myelofibrosis with myeloid metaplasia (MMM). To gain more information on mutational frequency, disease specificity, and clinical correlates, genomic DNA from 1182 patients with myeloproliferative and other myeloid disorders and 64 healthy controls was screened for MPL515 mutations, regardless of JAK2V617F mutational status: 290 with MMM, 242 with polycythemia vera, 318 with essential thrombocythemia (ET), 88 with myelodysplastic syndrome, 118 with chronic myelomonocytic leukemia, and 126 with acute myeloid leukemia (AML). MPL515 mutations, either MPLW515L (n = 17) or a previously undescribed MPLW515K (n = 5), were detected in 20 patients. The diagnosis of patients with mutant MPL alleles at the time of molecular testing was de novo MMM in 12 patients, ET in 4, post-ET MMM in 1, and MMM in blast crisis in 3. Six patients carried the MPLW515L and JAK2V617F alleles concurrently. We conclude that MPLW515L or MPLW515K mutations are present in patients with MMM or ET at a frequency of approximately 5% and 1%, respectively, but are not observed in patients with polycythemia vera (PV) or other myeloid disorders. Furthermore, MPL mutations may occur concurrently with the JAK2V617F mutation, suggesting that these alleles may have functional complementation in myeloproliferative disease.
authors.affiliation: Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA.
authors.forename: Animesh D
authors.initials: AD
authors.lastname: Pardanani
authors.forename: Ross L
authors.initials: RL
authors.lastname: Levine
authors.forename: Terra
authors.initials: T
authors.lastname: Lasho
authors.forename: Yana
authors.initials: Y
authors.lastname: Pikman
authors.forename: Ruben A
authors.initials: RA
authors.lastname: Mesa
authors.forename: Martha
authors.initials: M
authors.lastname: Wadleigh
authors.forename: David P
authors.initials: DP
authors.lastname: Steensma
authors.forename: Michelle A
authors.initials: MA
authors.lastname: Elliott
authors.forename: Alexandra P
authors.initials: AP
authors.lastname: Wolanskyj
authors.forename: William J
authors.initials: WJ
authors.lastname: Hogan
authors.forename: Rebecca F
authors.initials: RF
authors.lastname: McClure
authors.forename: Mark R
authors.initials: MR
authors.lastname: Litzow
authors.forename: D Gary
authors.initials: DG
authors.lastname: Gilliland
authors.forename: Ayalew
authors.initials: A
authors.lastname: Tefferi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001855:Bone Marrow Diseases / Q000453:epidemiology / Q000235:genetics; D016022:Case-Control Studies; D002675:Child, Preschool; D004252:DNA Mutational Analysis; D005260:Female; D005787:Gene Frequency; D005838:Genotype; D006801:Humans; D053614:Janus Kinase 2 / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D020125:Mutation, Missense; D009196:Myeloproliferative Disorders / Q000453:epidemiology / Q000235:genetics*; D053628:Receptors, Thrombopoietin / Q000235:genetics*
chemical_list: D053628:Receptors, Thrombopoietin; C082218:MPL protein, human; C507924:JAK2 protein, human; D053614:Janus Kinase 2